Cerus Corporation (NASDAQ:CERS) announced financial results for the first quarter ended March 31, 2015. Recent company highlights include: Signed INTERCEPT platelet and plasma supply …
Cerus Corporation (NASDAQ:CERS) will be presenting at the AABB Symposium on Implementation of Pathogen-Reduced Blood Components taking place in Bethesda, Maryland from April …
In a research report released today, MLV analyst George Zavoico reiterated a Buy rating on Cerus (NASDAQ:CERS) with a price target of $10, …
Just two days after approving Cerus’ (NASDAQ:CERS) INTERCEPT Blood System for Plasma, the FDA comes through and approves INTERCEPT Blood System for Platelets. …
MLV analyst George Zavoico is out again today with a new research note on Cerus (NASDAQ:CERS), raising his price target to $10 (from $7), while maintaining a …
In a research report issued today, MLV analyst George Zavoico reiterated a Buy rating on Cerus Corp. (NASDAQ:CERS) with a $7 price target, as the company announced …
In a research report published this morning, Cantor analyst Caroline Corner maintained a Buy rating on Cerus (NASDAQ:CERS) with a $6.00 price target, …
In a research note released today, MLV analyst George Zavoico reiterated a Buy rating on Cerus Corp. (NASDAQ:CERS) and raised his price target …
In a research note released today, MLV analyst George Zavoico reiterated a Buy rating on Cerus Corp. (NASDAQ:CERS) with a $6 price target, …
In a research note published yesterday, MLV analyst George Zavoico reiterated a Buy rating on Cerus (NASDAQ:CERS) with a $6 price target, on …